SynAct Pharma AB reported update from the 4-week RESOLVE P2a study of three doses of once-daily oral resomelagon (AP1189) in rheumatoid arthritis (RA) patients experiencing an incomplete response to methotrexate (MTX) therapy. Unblinded data from the study identified multiple irregularities in the conduct of the study and SynAct Pharma therefore needs to investigate the quality of the study in much more detail before making any conclusion on the results.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.84 SEK | -0.94% | -8.68% | -22.54% |
Mar. 20 | Sweden's SynAct Pharma Names New CEO | MT |
Mar. 20 | SynAct Pharma AB Elects New Board Members and Chairman at Extraordinary General Meeting | CI |
1st Jan change | Capi. | |
---|---|---|
-22.54% | 22.15M | |
-0.41% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.13% | 24.63B | |
-23.56% | 18.2B | |
+26.52% | 12.01B | |
-3.53% | 11.76B | |
+13.52% | 10.4B | |
-3.87% | 9.94B |
- Stock Market
- Equities
- SYNACT Stock
- News SynAct Pharma AB
- SynAct Pharma AB Announces Evaluation of the 4-Week RESOLVE P2a Clinical Trial in Moderate to Severe Active Rheumatoid Arthritis Patients with an incomplete Response to Methotrexate